Sanofi has received a show cause notice from the GST authorities proposing a tax, interest and penalty demand aggregating to INR 16.40 crore in relation to alleged discrepancies in its GST filings for FY 2022-23.
The company said the notice, dated September 28, 2026, relates to discrepancies between the value of supplies disclosed in e-way bills and the corresponding disclosures in GSTR-1.
The notice also raises issues concerning reconciliation of turnover reported in GSTR-9C with the turnover considered in GSTR-1 and the gross turnover reported by the company.
Further, the GST authorities have alleged short reversal of input tax credit and availment of certain input tax credits that were allegedly ineligible under applicable GST laws.
The proposed demand comprises tax, interest and penalty aggregating to Rs 16,40,07,641.
Sanofi said it is examining the show cause notice in consultation with its consultants and tax advisors and will take appropriate steps, including submitting its reply within the prescribed time period.
The company said it does not envisage any adverse impact on its financials, operations or other activities arising from the show cause notice.
